Objective: To determine whether pimobendan has in vitro antithrombotic properties through inhibition of platelets in canine blood samples.
Animals: 10 healthy adult dogs.
Procedures: Blood samples were collected from each dog into tubes containing hirudin or sodium citrate.
Objective: To establish practical doses and administration frequencies of fondaparinux for cats that would approximate human therapeutic peak and trough plasma anti-factor Xa activities for thromboprophylaxis (TP) and thrombosis treatment (TT) protocols.
Animals: 6 healthy adult purpose-bred cats.
Procedures: Dosage protocols for TP and TT were selected on the basis of a single compartment pharmacokinetic model incorporating data from humans but modified to account for the higher body weight-normalized cardiac output of cats.